FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 586 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Tarlatamab Shows Promise in Patients with Previously Treated Small-Cell Lung Cancer October 31, 2023 FDA Approves Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma February 12, 2021 FDA Approves Durvalumab for Muscle Invasive Bladder Cancer May 2, 2025 Telehealth-Based Cancer Care Surged during COVID. Will It Continue? March 9, 2022 Load more HOT NEWS Study presents an AI-guided approach to target cancer antigens ‘Inside Edition’ Anchor Thanks Viewer For Pointing Out Lump That Turned... Time to take on 9 new Cancer Grand Challenges Catch up on Behind the Science 2021 – From funding stream...
